| scholarly article | Q13442814 |
| P50 | author | Sreedhar Bodiga | Q48259153 |
| Maria B Grant | Q88523403 | ||
| Vaibhav B. Patel | Q42402068 | ||
| P2093 | author name string | Jennifer Lo | |
| Gavin Y Oudit | |||
| Zuocheng Wang | |||
| Ratnadeep Basu | |||
| Zamaneh Kassiri | |||
| Wang Wang | |||
| Subhash K Das | |||
| JiuChang Zhong | |||
| P2860 | cites work | Cardiac regulation by phosphoinositide 3-kinases and PTEN | Q24317248 |
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects | Q28286531 | ||
| Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress | Q28590326 | ||
| Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function | Q43267509 | ||
| Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. | Q43683472 | ||
| Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy | Q43935483 | ||
| Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells | Q44217757 | ||
| AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase | Q44504103 | ||
| Role of diabetes in congestive heart failure: the Framingham study | Q44758886 | ||
| Ca2+-independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy | Q45835938 | ||
| In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound | Q46698828 | ||
| Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies | Q46822459 | ||
| Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction | Q46838383 | ||
| Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling | Q46970404 | ||
| Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis | Q48577521 | ||
| Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. | Q51417559 | ||
| Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. | Q51772425 | ||
| Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. | Q54567739 | ||
| Relationship Between Coronary Microvascular Dysfunction and Cardiac Energetics Impairment in Type 1 Diabetes Mellitus | Q62396995 | ||
| Protein kinase C phosphorylation of cardiac troponin I or troponin T inhibits Ca2(+)-stimulated actomyosin MgATPase activity | Q67898066 | ||
| Crucial role of endothelium in the vasodilator response to increased flow in vivo | Q70275801 | ||
| Clinical and morphological features of human hypertensive-diabetic cardiomyopathy | Q70523586 | ||
| Pathways for angiotensin-(1---7) metabolism in pulmonary and renal tissues | Q73127508 | ||
| Myocardial cell death in human diabetes | Q73281473 | ||
| TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation | Q82430948 | ||
| The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine | Q29547539 | ||
| Global and societal implications of the diabetes epidemic | Q29614551 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association | Q33728882 | ||
| Activation of protein kinase C isoforms and its impact on diabetic complications | Q33881442 | ||
| Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction | Q33976308 | ||
| Molecular insights and therapeutic targets for diabetic endothelial dysfunction | Q34022332 | ||
| Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice | Q34156036 | ||
| Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator | Q34209959 | ||
| Pathways of angiotensin-(1-7) metabolism in the kidney | Q34258999 | ||
| Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone | Q34378188 | ||
| Oxidative stress and cardiovascular injury: Part II: animal and human studies | Q34542841 | ||
| Irbesartan in patients with heart failure and preserved ejection fraction | Q34877640 | ||
| Molecular understanding of hyperglycemia's adverse effects for diabetic complications | Q35005662 | ||
| The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction | Q35148421 | ||
| Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit | Q35152116 | ||
| Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis | Q35229424 | ||
| Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury | Q35916066 | ||
| Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis | Q35990801 | ||
| The renin-angiotensin-aldosterone system, glucose metabolism and diabetes | Q36088736 | ||
| Diabetic cardiomyopathy: the search for a unifying hypothesis | Q36423632 | ||
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | Q36548154 | ||
| Diabetic cardiomyopathy revisited | Q36860318 | ||
| Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function | Q36967674 | ||
| Insulin signalling in the heart | Q37129268 | ||
| The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. | Q37425444 | ||
| Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor | Q37513098 | ||
| Treatment of heart failure with normal ejection fraction: an inconvenient truth! | Q37691647 | ||
| Role of ACE2 in diastolic and systolic heart failure. | Q37884450 | ||
| Tissue inhibitor of metalloproteinases (TIMPs) in heart failure | Q37895982 | ||
| Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus | Q41700541 | ||
| Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase | Q42463456 | ||
| Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro | Q42518792 | ||
| Neprilysin, obesity and the metabolic syndrome | Q42610866 | ||
| Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction | Q43266255 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 10 | |
| P921 | main subject | circulatory system | Q11068 |
| systole | Q496359 | ||
| P304 | page(s) | 1322-1335 | |
| P577 | publication date | 2012-04-03 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis | |
| P478 | volume | 110 |
| Q28072451 | A Disintegrin and Metalloprotease 17 in the Cardiovascular and Central Nervous Systems |
| Q98388019 | ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2 |
| Q36392875 | ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity |
| Q38567063 | ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension |
| Q100558878 | ACE2 mouse models: a toolbox for cardiovascular and pulmonary research |
| Q38086829 | ACE2, angiotensin-(1–7), and Mas: the other side of the coin |
| Q41032759 | ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity |
| Q38238027 | ACE2/Ang-(1-7) signaling and vascular remodeling |
| Q34866649 | ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury |
| Q36720543 | Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors |
| Q47246338 | Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgαq*44 mice. |
| Q36990241 | Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. |
| Q46929763 | Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity |
| Q91703665 | Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q42256221 | Angiotensin II downregulates ACE2-mediated enhancement of MMP-2 activity in human cardiofibroblasts |
| Q39044195 | Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. |
| Q38193206 | Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling |
| Q38207841 | Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets |
| Q94553710 | Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad? |
| Q36087047 | Antagonism of angiotensin 1-7 prevents the therapeutic effects of recombinant human ACE2 |
| Q92689015 | Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs |
| Q90698406 | Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency |
| Q35086438 | Cardiac steatosis potentiates angiotensin II effects in the heart |
| Q35148756 | Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy. |
| Q92097301 | Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice |
| Q28293366 | Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts |
| Q99708624 | Dual deficiency of angiotensin-converting enzyme-2 and Mas receptor enhances angiotensin II-induced hypertension and hypertensive nephropathy |
| Q54305824 | Dual loss of PI3Kα and PI3Kγ signaling leads to an age-dependent cardiomyopathy. |
| Q42776028 | Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor |
| Q38680112 | Endothelial dysfunction and vascular disease - a 30th anniversary update |
| Q38679303 | Future drug discovery in renin-angiotensin-aldosterone system intervention |
| Q51146770 | Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. |
| Q42184716 | Hydrogen sulfide: an old gas with new cardioprotective effects. |
| Q36485537 | Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging |
| Q38124176 | Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure |
| Q37194713 | Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. |
| Q94594236 | Interactions between antihyperglycemic drugs and the renin-angiotensin system: Putative roles in COVID-19. A mini-review |
| Q36350590 | Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. |
| Q57750182 | Loss of Angiotensin-Converting Enzyme 2 Exacerbates Diabetic Retinopathy by Promoting Bone Marrow Dysfunction |
| Q46919923 | Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure |
| Q42402000 | Loss of TIMP3 selectively exacerbates diabetic nephropathy |
| Q90539466 | Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes |
| Q94502928 | Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure |
| Q38180800 | Modulation of the action of insulin by angiotensin-(1-7). |
| Q89052824 | Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA |
| Q37271294 | Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney |
| Q99544126 | Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral-bacterial interactions |
| Q34733168 | PI3K/AKT signaling pathway plays a role in enhancement of eNOS activity by recombinant human angiotensin converting enzyme 2 in human umbilical vein endothelial cells. |
| Q51308924 | PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. |
| Q60300789 | PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease |
| Q28468333 | Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis |
| Q38069197 | Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system |
| Q58803102 | Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α' |
| Q97523112 | Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 |
| Q38170474 | Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. |
| Q37081415 | Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure |
| Q49663340 | TIMP3 deficiency exacerbates iron-overload mediated cardiomyopathy and liver disease |
| Q64100814 | The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights |
| Q90299244 | The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs |
| Q36550987 | The renin angiotensin aldosterone system and insulin resistance in humans |
| Q99571376 | The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm |
| Q28077454 | Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease |
| Q27308039 | Upregulation of Angiotensin (1-7)-Mediated Signaling Preserves Endothelial Function Through Reducing Oxidative Stress in Diabetes. |
Search more.